Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 4/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 1.00 |
| ▸ | C9 | P02748 | 3/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | APEX1 | P27695 | 2/20 | 1.00 |
| ▸ | CTH | P32929 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | HSPD1 | P10809 | 2/20 | 1.00 |
| ▸ | THRB | P10828 | 2/20 | 1.00 |
| ▸ | HPGD | P15428 | 2/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 2/20 | 1.00 |
| ▸ | BRCA1 | P38398 | 2/20 | 1.00 |
| ▸ | RECQL | P46063 | 2/20 | 1.00 |
| ▸ | HSPE1 | P61604 | 2/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aurintricarboxylic Acid SCHEMBL29353681 | 1.00 | MEN1 (1.00) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL98495 | 1.00 | MEN1 (1.00) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL29395768 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL10791075 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL30831678 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL4644958 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL6158321 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL515038 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL15874321 | 0.99 | MEN1 (0.97) | MEN1KMT2AC9CYP2C9CYP2C19 | |
| Aurintricarboxylic Acid SCHEMBL6847597 | 0.97 | MEN1 (0.95) | MEN1KMT2AC9CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240277742-A1 | TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG | CHI BIOTECH CO., LTD. (CN) | 2024-08-22 | — | — | US | claimed |
| WO-2023138011-A1 | TRANSLATION INHIBITOR NOT OCCUPYING RIBOSOME RESOURCE AS ANTITUMOR DRUG | 深圳承启生物科技有限公司 | 2023-07-27 | — | — | WO | claimed |
| US-20240277742-A1 | TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG | CHI BIOTECH CO., LTD. (CN) | 2024-08-22 | — | — | US | disclosed |
| US-20230295191-A1 | A POLYESTER MOLDING COMPRISING A METAL-ORGANIC FRAMEWORK HAVING A LOW OUTGASSING OF VOLATILE ORGANIC COMPOUNDS | BASF SE (DE) | 2023-09-21 | — | — | US | disclosed |
| WO-2023138011-A1 | TRANSLATION INHIBITOR NOT OCCUPYING RIBOSOME RESOURCE AS ANTITUMOR DRUG | 深圳承启生物科技有限公司 | 2023-07-27 | — | — | WO | disclosed |
| EP-4188993-A1 | A POLYESTER MOLDING COMPRISING A METAL-ORGANIC FRAMEWORK HAVING A LOW OUTGASSING OF VOLATILE ORGANIC COMPOUNDS | BASF SE (DE) | 2023-06-07 | — | — | EP | disclosed |
| CN-114404400-A | Translation inhibitor without occupying ribosome resource as antitumor drug | 深圳承启生物科技有限公司 | 2022-04-29 | — | — | CN | disclosed |
| WO-2022029078-A1 | A POLYESTER MOLDING COMPRISING A METAL-ORGANIC FRAMEWORK HAVING A LOW OUTGASSING OF VOLATILE ORGANIC COMPOUNDS | BASF SE (DE) | 2022-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277742-A1 | TRANSLATION INHIBITOR WITHOUT OCCUPYING RIBOSOME RESOURCES AS ANTI-TUMOR DRUG | RACK1, RPL30, RRBP1 | MEN1 3445/4885KMT2A 1981/4885C9 4860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.